drugset

drugset / Trial / NCT00237120

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

NCT00237120 ↗

Phase 3 Completed 100 enrolled Novartis

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.

Timeline

Start: 2002-11
Primary completion: —
Completion: 2007-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	—	—

Indications